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The induction of immunologic tolerance is an important clinical goal in autoimmunity. CD4+ regulatory T (Treg) cells, deﬁned
by the expression of the transcription factor forkhead box P3 (FoxP3), play a central role in the control of autoimmune responses.
Quantitative and qualitative defects of Tregs have been postulated to contribute to failed immune regulation in multiple sclerosis
(MS) and other autoimmune diseases. This paper highlights the potential uses of T regulatory cell epitopes (Tregitopes), natural
Treg epitopes found to be contained in human immunoglobulins, as immunomodulating agents in MS. Tregitopes expand Treg
cells and induce “adaptive Tregs” resulting in immunosuppression and, therefore, are being considered as a potential therapy
for autoimmune diseases. We will compare Tregitopes versus intravenous immunoglobulin (IVIg) in the treatment of EAE with
emphasis on the potential applications of Tregitope for the treatment of MS.
1. MultipleSclerosisandtheAdaptiveImmunity
Multiple sclerosis (MS) aﬀects over 2 million people world-
wide and is the leading cause of neurological disability in
young adults. It is now clear that the core process in MS is
inﬂammatory, with myelin-reactive T helper (TH) cells and
their mediators triggering injury of axons and their myelin
sheaths through a complex sequence of events [1]. Experi-
mental autoimmune encephalomyelitis (EAE) has been used
as a model for MS for more than 40 years and has been a
majorfactorindetermining thepathofMSresearch.InEAE,
TH1andT H17eﬀectorcells,majorproducersofIFNγ andIL-
17,respectively,havebeenassociatedwiththediseasecascade
that causes encephalitogenicity [2–6]. The observation that
IFNγ and IL-17 expression were upregulated in peripheral
circulating T cells as well as in the central nervous system
of MS patients gave validity to the hypothesis that TH1a n d
TH17cellswerepotentiallypathogenicinMSpatients[7–11].
Thus, current therapies for MS are immunomodulatory and
have been eﬀective in decreasing relapse rates but seemingly
far less eﬀective in preventing disease progression, deﬁned as
an accumulation of neurologic disability.
Although immune dysregulation had been described in
MS patients for some time, a major breakthrough came
in the 1990s with the discovery of a speciﬁc subtype of
CD4+CD25+ suppressorTcells(nowcalledregulatoryTcells
or Tregs) [12]. Treg cells are a specialized subpopulation of
T cells that act to suppress activation of undesirable immune
responsesandtherebymaintainimmunesystemhomeostasis
and tolerance to self-antigens. At least two major subtypes of
T r e g sh a v eb e e ni d e n t i ﬁ e d :n a t u r a lT r e g s( n T r e g s )g e n e r a t e d
in the thymus and inducible Tregs (iTregs) generated in the
periphery from CD4+CD25−FoxP3− eﬀector T cells. Almost
a decade after their discovery, the Haﬂer group described
ﬁrst a functional defect of peripheral CD4+CD25+ Tregs in
patients with relapsing-remitting MS [13] that was followed
by several reports conﬁrming these observations in MS
patients [14, 15]. Thus, therapy that restores impaired nTreg
cellhomeostasiswhilesuppressingpathogeniceﬀectorTcells
(TH1a n dT H17) at the right time and more importantly at2 Neurology Research International
the right place will be a promising approach in MS patients.
Adoptive cell transfer of patient-speciﬁc CD4+CD25+ Tregs
has been considered a potential therapeutic approach [16].
Strategies aimed at expanding Tregs in patients with autoim-
mune diseases are viewed as promising. The technical barrier
in translating this strategy to clinical practice is to ﬁnd
safe and eﬀe c t i v em e t h o dt oi n d u c eT r e g sa n ds u p p r e s so r
convert eﬀector cells to adaptive Tregs in the target organs in
autoimmune diseases.
2. Discovery of Tregitopes
T regulatory cell epitopes (Tregitopes) were discovered when
the team of De Groot et al. [17] was searching for poten-
tial eﬀector T-cell epitopes in monoclonal antibodies and
uncovered several strong signals for T cell responses in the
Fc and Fab domains of IgG antibodies. To identify these
epitopes, they used EpiMatrix, an epitope mapping tool, and
ClustiMer, a promiscuous epitope mapping tool [18]. These
putative T-cell epitope sequences were highly conserved
acrossIgGisotypesandinpublishedIgGsequencedatabases,
suggesting that they were functional (Figure 1). Indeed, the
peptides representing these highly conserved, promiscuous
regions appeared to suppress immune responses in coculture
and the expanded cells exhibited surface marker charac-
teristics and the cytokine proﬁle of Tregs [17]. Tregitopes
are peptides that have the following four characteristics: (i)
their sequences are highly conserved in similar autologous
proteins, (ii) they almost all exhibit “EpiBars” or a pattern
(asmeasuredbyEpiMatrix)thatsuggestspromiscuousMHC
binding [19], (iii) T cells responding to these Tregitopes ex-
hibit a T regulatory phenotype (CD4+CD25+FoxP3+)a n d
secrete IL-10, TGF-β and MCP-1 ([17] and unpublished
observations), and (iv) coincubation of Tregitopes with im-
munogenic peptides inhibits T cell proliferation in vitro and
suppresses the secretion of eﬀector cytokines and chemoki-
nes in response to the immunogenic peptides.
Prior to the discovery of Tregitopes, no Treg cells that
respond to Ig epitopes had been identiﬁed nor had nTregs
reacting to Ig been used to induce adaptive tolerance. We
have proposed that Tregitope recognition by Tregs initiates
a series of events that culminate in (i) suppression of effector
T cell immune responses in the immediate vicinity of the
activated Treg (bystander suppression) and/or (ii) induction
of antigen-speciﬁc iTregs which downregulate immune re-
sponses to a given antigen.
A description of the initial two Tregitopes (289 and 167,
both in the heavy chain of IgG) was published in Blood
in 2008 [17]. When added to a culture of freshly isolated
human peripheral blood mononuclear cells ex vivo, these
Tregitopes led to an expansion of the number of Tregs and/or
an upregulation of FoxP3 expression in previously FoxP3-
negative T cells. We also demonstrated (i) induction of
natural Tregs in a four day incubation and (ii) a phenotype
change in eﬀector T cells incubated with the Tregitopes away
fromIL-5secretingcellstonullcellsandincreasedexpression
of adaptive Treg cell surface proteins (GITR and CTLA-4)
[17]. Coadministration of the Tregitopes in vivo with dust
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Figure 1: (a) Approximate location of IgG “Tregitopes” EpiVax
murine and human Tregitope peptides. (b) Human and mouse Tre-
gitopes are highly conserved. The sequences in bold are considered
the core Tregitope sequence and diﬀerences are color coded.
mite antigens suppresses immune response to the antigens,
and this response is partially dependent on the presence of
regulatory T cells (as deﬁned by the cell surface markers
CD4+ and CD25hi and intracellular FoxP3).
2.1. Tregitopes and Tolerance. It has become increasingly
clear that CD4+CD25+ regulatory T cells are an important
component of immune regulation in the periphery. Autore-
active T cells with moderate aﬃnity may escape thymic
deletion and be converted to function as eﬀector cells or
“natural” regulatory T cells. These moderate binding Treg
cells are exported to the periphery, where they provide a
source of protective immunity against foreign antigens or
suppression of immunity against self-antigens. It has been
suggested that T cells must be tolerant to Ig molecules that
have undergone somatic hypermutation following primary
engagement of the variable region with an antigen [20].
Indeed, it has been observed that tolerance induction in a
murine diabetes model using delivery of Fc fusion proteins
in B cells is due to induction of regulatory T cells [21].Neurology Research International 3
2.2. Dendritic Cells (DCs). Dendritic cells are essential to
generate and maintain immunological tolerance. They are
critical intermediaries between antigens and lymphocytes.
DCs sample peripheral antigens in the skin, gastrointestinal
and respiratory epithelia, migrate to the T cell areas of
lymphoid tissue, where they activate and expand antigen-
speciﬁc helper and killer T cells [22]. They are known as
“professional antigen presentation cells”, because they eﬃ-
ciently process and present antigen-derived peptides in the
context of MHC. Respectively, CD8+ and CD4+ Tc e l l s
recognize MHC I: peptide and MHC II: peptide complexes
and initiate the adaptive immune response [23, 24]. In
addition to their role as mediators of immune responses,
DCs play a critical role in the induction of regulatory T cells
[25]. DC-SIGN (dendritic cell-speciﬁc intercellular adhesion
molecule-3-grabbing nonintegrin), a C-type lectin mainly
present at the surface of immature dendritic cells, plays
a relevant role activating and tailoring adaptive immune
responses against diﬀerent pathogens. This lectin recognizes,
in a multivalent and calcium-dependent manner, highly gly-
cosylated proteins present at the surface of pathogens [26].
In studies carried out by Anthony et al. in the Ravetch group
[27], tolerance was induced following treatment of collagen-
induced arthritis with sialylated intravenous immunoglobu-
lin (IVIg) Fc fragments. The eﬃcacy of sialylated-Fc, which
isbelievedtobemoreeﬃcientlytakenupbyDC-SIGN could
be explained by the presence of Tregitope in the Fc. However,
in the Ravetch studies, tolerance induction required Fc-
sialylation, which has not been required for studies carried
out by Khoury and Elyaman and De Groot et al. [28]a n d
[17]). Tregitopes administered in saline are able to suppress
immune response to antigen, and the aﬃnity of binding to
HLA correlates with their suppression ability suggesting that
the natural receptor for Tregitopes contained in IgG Fc is the
human HLA molecule.
One explanation that may tie the two observations to-
gether is that DC-SIGN may enable the traﬃcking of sialy-
lated IgG to the antigen processing and presentation path-
way. The requirement for sialylation does not explain the
induction of natural and inducible Tregs following admin-
istration of Tregitope peptides in saline [17]. Our ﬁndings
are strengthened by reports that polyclonal immunoglobulin
therapies induce expansion of Tregs and IL-10 secretion in
vivo in animals and humans [29–31]. Others have described
the immunosuppressive eﬀects of non-Fc IgG-derived pep-
tides (included in ourlist of Tregitopes [23,32,33]providing
independent conﬁrmation of the hypothesis.
3.Tregitopes versusIVIg
The important discovery of Tregitopes has the potential to
bring understanding about a number of phenomena related
to Ig, including tolerance to antibody (Ab) variable regions,
the tolerogenic properties of immunoglobulin-antigen (Ag)
conjugates, the weak immunogenicity of Fc fusion proteins,
and the therapeutic and regulatory eﬀects of clinical prepa-
rations of intravenous immunoglobulin (IVIg) on autoim-
mune and inﬂammatory diseases. Immunoglobulin (Ig) has
long been known to have tolerogenic properties. Thus, Ags
conjugated to Ig elicit tolerance rather than immunity, and
intravenous administration of pooled Ig from multiple do-
nors, known as IVIg, is used in clinical practice to treat auto-
immune and inﬂammatory diseases.
The presence of Tregitopes in IgG may explain the
induction of tolerance with intravenous IgG (Figure 2). Even
though the role of immunoglobulin in tolerance was pos-
tulated in studies published almost a century ago [34], the
mechanism behind antibody-mediated immune suppression
has remained unclear. Some studies have shown that the Fab
region is as capable of inducing suppression as well as intact
antibodieswithanFcregion(whichwouldbeconsistentwith
our discovery of Tregitopes in both the Fab and Fc regions)
[35], while other studies indicate that Fc, Fab, and intact
IgG was incapable of immune suppression [36]. In some
cases, the authors postulated that the immune suppression
may be due to the interaction of the Fc domain with yet
to be discovered Fcγ receptors, and others have concluded
that the eﬀect is due to Fc-independent mechanisms such as
epitope masking [36], while still others provide only a broad
explanation wherein the type of immune response (eﬀector
or tolerance) to a given antibody idiotype is attributed to the
isotype of the antibody and the potential immunogenicity of
their idiotypes [37]. Of note, Kessel et al. recently showed
thatIVIg“improvedthesuppressivefunction”ofnTregs[38].
ThepresenceorabsenceofTregitopeshasbeenassociated
with immune responses to monoclonal antibodies in clinical
studies. Immunogenicity occurs despite “humanization” of
antibodies as demonstrated in [18]. Indeed, a careful review
of monoclonal antibody immunogenicity in clinical practice
has revealed a correlation between the presence of hTregit-
opes and lower immunogenicity of monoclonal antibodies
in human studies; a signiﬁcant (P < 0.002) correlation was
found between Tregitope content and lower reported immu-
nogenicity (reported in De Groot and Martin’s analysis of 21
monoclonals in current clinical use [18]).
This model does not ignore the contribution of Fc re-
ceptors to IgG-mediated anti-inﬂammatory processes. Fc-
gamma Receptors (FcγR) are required for rapid uptake of
IgG and immune complexes into antigen-presenting cells
during the initial inﬂammatory phase, and the inhibitory Fc
receptor, FcγRIIb, increases the threshold for cell activation
during the refractory phase of immune response. In our
model, Tregitope activation of Treg would stimulate the
release of cytokines such as IL-4 and IL-10 that are known
to shift expression from the activating FcγRI and FcγRIIa to
FcγRIIb [33].
Immunization with antigens fused to the IgG Fc region
is now a well-established method of tolerizing against the
antigen. For example, Baxevanis et al. evaluated the eﬀect
of administering human Fc (hFc) to mice in 1986 [39],
causing tolerance rather than antihuman immune response.
These studies were eventually replicated by Scott et al., who
showed that (i) fusion of an IgG heavy chain to antigen,
or administration of the Fc region in conjunction with the
antigen, could induce tolerance, (ii) MHC class II molecules
were required for induction of tolerance [40], and (iii)
the human Fc region plays an essential role in immune4 Neurology Research International
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Figure 2: Proposed role of Tregitopes in IgG. Adapted with permission from de Groot et al. [18]. Antibody-derived Treg epitope (dark blue)
activated regulatory T cells (Treg), which leads to suppression of eﬀe c t o rTc e l l s( T e ﬀ) that recognize eﬀector epitope (red), like those of IgG
hypervariable regions to which central tolerance does not exist.
suppression by IgG fusion, but Fc binding is not required
[41]. Furthermore,mice have homologous T regulatory epit-
opes, which may explain earlier observations that Fc [39]
and Fc-protein fusions [42] stimulate a tolerizing immune
response.
4.Tregitopes inAutoimmunity
The discovery of Tregitopes inspired a reconsideration of
published research on IVIg and Fc-fusions. The Tregitope
hypothesis may change the interpretation of work published
almost a century ago [34]a sw e l la sm o r er e c e n ts t u d i e sa s -
sociating an immunosuppressive eﬀect with the Fc fragment
of IgG. Preliminary studies generated by Khoury and col-
leagues provided proof that stimulation of antigen-speciﬁc
T cells in the presence of the IgG-derived Tregitope-speciﬁc
natural Tregs induces adaptive tolerance to the myelin
antigen-mediated autoimmune encephalomyelitis by tipping
the immune response toward anti-inﬂammatory phenotype
[28].
A study published by Ephrem et al. in Blood also dem-
onstrated that IVIg therapy induced expansion of Tregs and
protected against development of EAE induced by active
immunization with myelin oligodendrocyte glycoprotein
(MOG)35–55 [43]. IVIg has been considered as a potential
systemic therapy for MS and other autoimmune diseases
[44, 45]; however, the use of human IVIg is associated with
a number of real and potential adverse eﬀects [46, 47]. In
order to explore a safer, more eﬀective alternative to IVIg
for the treatment of MS, we have evaluated the capacity of
IgG-derived Tregitopes to generate antigen-speciﬁc adaptive
tolerance induction to MOG35–55 epitopes in vivo. Our
ﬁndings point to a tolerogenic eﬀect of Tregitopes coadmin-
istration on immune responses to the MOG35–55 epitopes
in vitro and in vivo, a result consistent with the results of
Zaghouani and coworked using IgG fusion proteins with
CNS antigens [48]. The success of Tregitopes in suppressing
experimental autoimmunity may lead to their use as a ther-
apy for MS. Successful development of Tregitope therapy
would have a radical impact on the ﬁelds of autoimmunity,
transplantation, and protein therapeutics and may lead to
development of an alternative to IVIg.
5. Conclusion
Is there a role for Tregitope in future clinical practice?
Emerging approaches to autoimmune disease treatment
currently involve induction of Tregs using monoclonal anti-
bodies (mAbs) such as anti-CD3 (Teplizumab, Macrogenics,
Otelixizumab, and Tolerx), which induce Treg cells. Anti-
CD3 treatment has shown some eﬃcacy in human studies,
but the mechanism of Treg induction is elusive and the
eﬀect appears to be short lasting [49, 50]. Antigen speciﬁcity
and localized immunosuppressive eﬀects are believed to be
advantages of the Tregitope approach that might reduce side
eﬀects (such as infections) associated with more broadly
suppressive treatments. Our prior studies indicate that the
eﬀect of Tregitopes may be long lasting in mice (100 days
in the transplant model, and up to 30 weeks in NOD mice
(De Groot et al., submitted), but maintenance of tolerance
in humans may require “booster” treatments and/or inter-
mittent low-dose IL-2 to maintain Treg populations [51].
Induction of tolerance using Tregitope therapy would allevi-
ate the burden of repeated and long-term medical interven-
tions associated with chronic autoimmune diseases. The use
of Tregitopes may be a safe and eﬀective approach to expand
natural Tregs in autoimmune diseases such as MS and in
transplantation.
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